Literature DB >> 19515559

Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.

Bhaskar C Das1, Ankanahlli V Madhukumar, Jaime Anguiano, Sridhar Mani.   

Abstract

A small library of 2H-benzo[b][1,4] oxazine derivative was synthesized and their biological activity was tested on HepG2 cells under normoxic and hypoxic conditions. From preliminary screening, we found compound 10 and 11 specifically inhibit hypoxic cancer cell growth IC(50) 87+/-1.8microM and IC(50) 10+/-3.7microM while sparing 'normoxic' cells IC(50) >600M and >1mM (not applicable), respectively. We tested the effect of 10 on MTT, clonogenic and hypoxia induced genes. The MTT correlates with clonogenic assays and most importantly compound 10 down regulates hypoxia induces genes (HIF-1alpha, P21 and VEGF) appropriately. We are in the process to explore the molecular mechanism of action of oxazine derivative compounds on hypoxia tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515559      PMCID: PMC2882196          DOI: 10.1016/j.bmcl.2009.05.110

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  18 in total

1.  Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine.

Authors:  Nicola L Brown; Nicholas R Lemoine
Journal:  Methods Mol Med       Date:  2004

2.  DIHYDRO-1,3-OXAZINES AS ANTITUMOR AGENTS.

Authors:  M E KUEHNE; E A KONOPKA
Journal:  J Med Pharm Chem       Date:  1962-03

3.  Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

Authors:  Kongming Wu; Chenguang Wang; Mark D'Amico; Richard J Lee; Chris Albanese; Richard G Pestell; Sridhar Mani
Journal:  Mol Cancer Ther       Date:  2002-07       Impact factor: 6.261

4.  Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins.

Authors:  Hugo Cerecetto; Mercedes González; Ma Laura Lavaggi; Amaia Azqueta; Adela López de Cerain; Antonio Monge
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

5.  A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

Authors:  Kyriakos P Papadopoulos; Sanjay Goel; Murali Beeram; Alvin Wong; Kavita Desai; Missak Haigentz; María L Milián; Sridhar Mani; Anthony Tolcher; Alshad S Lalani; John Sarantopoulos
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.

Authors:  Mark R Albertella; Paul M Loadman; Philip H Jones; Roger M Phillips; Roy Rampling; Neil Burnet; Chris Alcock; Alan Anthoney; Egils Vjaters; Chris R Dunk; Peter A Harris; Alvin Wong; Alshad S Lalani; Chris J Twelves
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

7.  Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells.

Authors:  Rachida S Belaiba; Steve Bonello; Christian Zähringer; Stefanie Schmidt; John Hess; Thomas Kietzmann; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2007-09-26       Impact factor: 4.138

Review 8.  The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions.

Authors:  P H Rooney; C Telfer; M C E McFadyen; W T Melvin; G I Murray
Journal:  Curr Cancer Drug Targets       Date:  2004-05       Impact factor: 3.428

9.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Authors:  G L Wang; B H Jiang; E A Rue; G L Semenza
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Authors:  Adam V Patterson; Dianne M Ferry; Shelley J Edmunds; Yongchuan Gu; Rachelle S Singleton; Kashyap Patel; Susan M Pullen; Kevin O Hicks; Sophie P Syddall; Graham J Atwell; Shangjin Yang; William A Denny; William R Wilson
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

View more
  4 in total

Review 1.  Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009.

Authors:  Roland E Dolle; Bertrand Le Bourdonnec; Karin Worm; Guillermo A Morales; Craig J Thomas; Wei Zhang
Journal:  J Comb Chem       Date:  2010-10-05

2.  Design, synthesis and biological study of pinacolyl boronate-substituted stilbenes as novel lipogenic inhibitors.

Authors:  Bhaskar C Das; Xiaoping Zhao; Xiang-Ying Tang; Fajun Yang
Journal:  Bioorg Med Chem Lett       Date:  2011-06-28       Impact factor: 2.823

3.  Novel retinoic acid receptor alpha agonists for treatment of kidney disease.

Authors:  Yifei Zhong; Yingwei Wu; Ruijie Liu; Zhengzhe Li; Yibang Chen; Todd Evans; Peter Chuang; Bhaskar Das; John Cijiang He
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

4.  Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives.

Authors:  Jaime Anguiano; Thomas P Garner; Murugesan Mahalingam; Bhaskar C Das; Evripidis Gavathiotis; Ana Maria Cuervo
Journal:  Nat Chem Biol       Date:  2013-04-14       Impact factor: 15.040

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.